Question 1

What was the main purpose of the REWIND trial?

Accepted Answer

To assess how the GLP-1 receptor agonist dulaglutide affects major adverse cardiovascular events when added to existing diabetes treatments in people with type 2 diabetes with and without previous cardiovascular disease.

Question 2

Who participated and how was the study conducted?

Accepted Answer

Men and women aged at least 50 with type 2 diabetes and either prior cardiovascular events or cardiovascular risk factors were randomized 1:1 to weekly dulaglutide 1.5 mg or placebo in a multicentre, randomized, double-blind, placebo-controlled design.

Question 3

What were the key results for cardiovascular outcomes and mortality?

Accepted Answer

The primary composite cardiovascular outcome occurred in 12.0% with dulaglutide vs 13.4% with placebo (HR 0.88; p=0.026). All-cause mortality was 10.8% vs 12.0% (HR 0.90; p=0.067), which was not statistically significant.